Completed PHASE1 INTERVENTIONAL 4-arm NCT04428593

Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers

Double Blind, Randomized, Placebo-controlled Study of Safety and Tolerability of Treamid in Rising Doses at Single and Then Multiple Oral Administration in Healthy Volunteers

Sponsor: PHARMENTERPRISES LLC

Conditions Metabolic Syndrome

Interventions Placebo Treamid 15 mg Treamid 5 mg Treamid 50 mg

Updated 4 times since 2020 Last updated: Jun 15, 2020 Started: Jan 25, 2016 Primary completion: Nov 21, 2016 Completion: Nov 21, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04428593, this PHASE1 trial focuses on Metabolic Syndrome and remains completed. Sponsored by PHARMENTERPRISES LLC, it has been updated 4 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jul 2020 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PHARMENTERPRISES LLC

Data source: PHARMENTERPRISES LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.